LENSAR, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
March 16, 2023 at 07:31 am EDT
Share
LENSAR, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported revenue was USD 10.23 million compared to USD 11.22 million a year ago. Net loss was USD 2.49 million compared to USD 3.9 million a year ago. Basic loss per share from continuing operations was USD 0.24 compared to USD 0.41 a year ago. Diluted loss per share from continuing operations was USD 0.24 compared to USD 0.41 a year ago.
For the full year, the company reported revenue was USD 35.358 million compared to USD 34.459 million a year ago. Net loss was USD 19.914 million compared to USD 19.601 million a year ago. Basic loss per share from continuing operations was USD 1.96 compared to USD 2.09 a year ago. Diluted loss per share from continuing operations was USD 1.96 compared to USD 2.09 a year ago.
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its product portfolio consists of the LENSAR Laser System and ALLY Adaptive Cataract Treatment System (ALLY System) and its associated consumable components. The system incorporates a range of technologies designed to assist the surgeon in obtaining visual outcomes. The consumable portion of the system consists of a disposable patient interface device kit. The ALLY System is designed to combine its femtosecond laser technology features with enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room or in-office surgical suite. Its system is used across surgeons, hospital outpatient surgical facilities and ambulatory surgery centers.
LENSAR, INC. 
